Catalyst Pharmaceuticals, Inc. $CPRX Stake Boosted by UBS Group AG

UBS Group AG increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 648,987 shares of the biopharmaceutical company’s stock after purchasing an additional 55,378 shares during the quarter. UBS Group AG owned approximately 0.53% of Catalyst Pharmaceuticals worth $15,147,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CPRX. Deerfield Management Company L.P. increased its stake in Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. American Century Companies Inc. grew its stake in Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after acquiring an additional 770,198 shares in the last quarter. Fundsmith LLP grew its stake in Catalyst Pharmaceuticals by 24.2% during the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after acquiring an additional 654,721 shares in the last quarter. Glenmede Investment Management LP grew its stake in Catalyst Pharmaceuticals by 781.8% during the 3rd quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after acquiring an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Catalyst Pharmaceuticals by 30.6% during the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after acquiring an additional 554,200 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Finally, Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $31.16 on Thursday. The stock has a market cap of $3.81 billion, a PE ratio of 17.91, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The stock’s 50-day moving average is $25.86 and its two-hundred day moving average is $24.21.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).